Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "program"

1759 News Found

CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park
News | March 06, 2026

CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park

The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant


KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients
News | March 05, 2026

KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients

Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention


MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai
News | March 05, 2026

MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai

A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer


Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy
Clinical Trials | March 05, 2026

Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy

SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum


Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Clinical Trials | March 03, 2026

Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings


FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia
News | March 03, 2026

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications


SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
Digitisation | March 02, 2026

SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026

During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions


Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS
Clinical Trials | March 02, 2026

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology